Program
HSK31679
A development code. Also written as “HSK31679 80mg”, “HSK31679 160mg” and “[14C]HSK31679”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Hypercholesterolemia, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 52 open or running | phase 3since May 6, 2026 | Aug 24, 2022 | Jun 30, 2029phase 3 · NCT07581951 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2022First study: phase 1 study in HealthyFirst studyNCT05531097 · 96 enrolled · China
- Mar 9, 2023Phase 2 study in HypercholesterolemiaNCT05795517 · 210 enrolled · China
- Dec 5, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06168383 · 186 enrolled · China
- Feb 6, 2024Phase 1 study in HealthyNCT06258746 · 6 enrolled · China
- May 6, 2026Phase 3 study in Non-alcoholic Fatty Liver DiseasePhase 3 reachedNCT07581951 · 886 planned · China
Ahead
- Jun 30, 2029Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07581951
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07581951Non-alcoholic Fatty Liver Disease · China | 3 | Recruiting | Jun 30, 2029 | 886 |
| NCT06258746Healthy · China | 1 | Active, not recruiting | Dec 21, 2023 | 6 |
| NCT06168383Non-alcoholic Fatty Liver Disease · China | 2 | Completed | Dec 12, 2025 | 186 |
| NCT05795517Hypercholesterolemia · China | 2 | Completed | Feb 20, 2024 | 210 |
| NCT05531097Healthy · China | 1 | Completed | Sep 21, 2022 | 96 |
How it is read
Names in the registry
- “HSK31679”, 2 entries
- “HSK31679 80mg”, 1 entry
- “HSK31679 160mg”, 1 entry
- “[14C]HSK31679”, 1 entry
- “HSK31679 low dose”, 1 entry
Codes read as this program: HSK31679.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.